The Feasibility and Efficacy of Dose-Adjusted Bortezomib, Melphalan and Dexamethasone for Transplantation-Ineligible Patients with Newly Diagnosed Multiple Myeloma

Publisher： Karger

E-ISSN： 1421-9662|134|4|229-230

ISSN： 0001-5792

Source： Acta Haematologica, Vol.134, Iss.4, 2015-0, pp. : 229-230

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myeloma not eligible for or who deferred autologous stem cell transplantation

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 1, 2015-04 ,pp. : 36-43

John Wiley & Sons Inc

Access to resources Recommend Favorite

Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib‐melphalan‐prednisone in the phase III VISTA study

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 4, 2015-04 ,pp. : 314-319

John Wiley & Sons Inc

Access to resources Recommend Favorite

Subcutaneous bortezomib combined with weekly cyclophosphamide and dexamethasone is an efficient and well tolerated regime in newly diagnosed multiple myeloma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 5, 2015-06 ,pp. : 754-756

John Wiley & Sons Inc

Access to resources Recommend Favorite

Bortezomib‐thalidomide‐dexamethasone versus bortezomib‐cyclophosphamide‐dexamethasone as induction therapy prior to autologous stem cell transplantation in multiple myeloma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 168, Iss. 4, 2015-02 ,pp. : 605-606

John Wiley & Sons Inc

Access to resources Recommend Favorite

Immortal time bias and reverse causality in retrospective analysis: Comment on “effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib–melphalan–prednisone in the phase III VISTA study”

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 8, 2015-08 ,pp. : E146-E146

John Wiley & Sons Inc

Access to resources Recommend Favorite